CCR4: A Potential Drug Target for Various Diseases (G1233)
CCR4: A Potential Drug Target for Various Diseases
CCR4 (chemokine (C-C motif) receptor 4) is a protein that is expressed in various tissues throughout the body. It is a member of the chemokine receptor family, which is a subset of the G protein-coupled receptor (GPCR) family. CCR4 is involved in the regulation of cellular processes such as cell adhesion, migration, and signaling pathways that are important for various physiological processes in the body.
Recent studies have identified CCR4 as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases has led to the development of CCR4 antagonists as a new class of therapeutics.
The CCR4 receptor is composed of an extracellular domain, a transmembrane region, and an intracellular domain. The extracellular domain is involved in the formation of the receptor complex with its co-receptor, which is a protein that consists of a catalytic subunit and a non-catalytic subunit. The transmembrane region is responsible for the transfer of the intracellular signal from the receptor to the intracellular signaling pathway. The intracellular domain is involved in the regulation of the receptor's activity, including the interaction with ligands and the formation of the receptor-ligand complex.
CCR4 is involved in various signaling pathways that are important for cellular processes such as cell adhesion, migration, and angiogenesis. It has been shown to play a role in the regulation of cell-cell adhesion by interacting with the protein E-cadherin. CCR4 has also been shown to be involved in the regulation of cell migration and the establishment of tissue boundaries by interacting with the protein Z-catenin.
In addition to its role in cellular signaling pathways, CCR4 has also been shown to be involved in the regulation of inflammation and immune responses. It has been shown to play a role in the regulation of T-cell development and function by interacting with the protein PD-L1. CCR4 has also been shown to be involved in the regulation of inflammation by interacting with the protein NF-kappa-B.
The CCR4 receptor has also been shown to be involved in the regulation of pain perception and neurodegenerative diseases. It has been shown to play a role in the regulation of neurotransmitter release from neurons by interacting with the protein TrkB. CCR4 has also been shown to be involved in the regulation of the development and progression of neurodegenerative diseases by interacting with the protein APP/PDTx-4.
In conclusion, CCR4 is a protein that is involved in various signaling pathways that are important for cellular processes such as cell adhesion, migration, and angiogenesis. Its role in these processes makes it a potential drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The development of CCR4 antagonists as a new class of therapeutics has the potential to treat these diseases. Further research is needed to fully understand the role of CCR4 in these diseases and to develop effective treatments.
Protein Name: C-C Motif Chemokine Receptor 4
Functions: High affinity receptor for the C-C type chemokines CCL17/TARC, CCL22/MDC and CKLF isoform 1/CKLF1. The activity of this receptor is mediated by G(i) proteins which activate a phosphatidylinositol-calcium second messenger system. Can function as a chemoattractant homing receptor on circulating memory lymphocytes and as a coreceptor for some primary HIV-2 isolates. In the CNS, could mediate hippocampal-neuron survival
The "CCR4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCR4 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59
